cNeT (clonal neoantigen) process builds on TILs, combined with ability to identify pt-specific clonal neoantigens and generate personalized T-cell therapies. Sep19 GBP100 million Series B w/ RA, Syncona, Forbion, Invus, Perceptive + Redmile.
Phase l or ll, Pre-Clinical Stage
Immuno-Oncology, Immunotherapy, Oncology
Stevenage Bioscience Catalyst, Gunnels Wood Road
Stevenage, Herefordshire SG12FX
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.